Keyword: GlaxoSmithKline (GSK)

News

Novartis Lifts Full-Year Outlook After Competition Delay

18.07.2013 - Novartis raised its full-year outlook on Wednesday after generic competition to its best-selling blood pressure pill was delayed, granting the Swiss drugmaker a temporary reprieve...

News

GlaxoSmithKline Broke Law to Boost Sales Prices, China Police say

15.07.2013 - British drugmaker GlaxoSmithKline used travel agencies and consultancies as vehicles to bribe Chinese officials and doctors to illegally boost the sales prices of its medicines in...

News

China Says GSK Execs Confess To Bribery and Tax Crimes

12.07.2013 - GlaxoSmithKline executives in China have confessed to bribery and tax violations, the country's security ministry said on Thursday, during one of a string of investigations into...

News

GlaxoSmithKline to Use Immunocore Drug Technology

10.07.2013 - GlaxoSmithKline plans to exploit new technology from private British biotech company Immunocore to develop next-generation drugs against cancer that fight tumors in ways antibody...

News

GlaxoSmithKline Examines Chinese Botox Sales Tactics

09.07.2013 - GlaxoSmithKline said on Monday it was investigating new allegations that its staff had used improper tactics to market Botox in China, but had so far found no evidence of bribery...

News

GlaxoSmithKline Hit with New Chinese Bribery Allegations

08.07.2013 - China-based staff of GlaxoSmithKline allegedly handed doctors with cash and other rewards for prescribing Botox, according to the Wall Street Journal, in the latest scandal to hit...

News

GlaxoSmithKline Under Investigation in China

05.07.2013 - China's top economic planning agency has opened an investigation into pharmaceutical giant GlaxoSmithKline's operations in China, an official newspaper reported on Thursday, as...

News

Onyx Rejects Amgen Offer, Explores Possible Sale

01.07.2013 - Cancer drugmaker Onyx Pharmaceuticals said on Sunday it rejected a roughly $10 billion takeover offer from larger biotechnology company Amgen as too low but still is considering...